Biomea Fusion reported a net loss of $8.3 million for the quarter ended June 30, 2026, compared to $20.7 million in the prior year period. The company held $35.2 million in cash and cash equivalents as of June 30, 2026, with a projected cash runway extending into the second quarter of 2027. Clinical updates include ongoing enrollment for Phase II trials COVALENT-211 and COVALENT-212 evaluating icovamenib in Type 2 diabetes, with data expected in early 2027. Initial weight reduction data from the Phase I BMF-650 obesity trial is anticipated in the third quarter of 2026. The company also initiated a research collaboration with the University of Leicester to evaluate icovamenib combined with semaglutide for obesity. Biomea Fusion operates as a clinical-stage biopharmaceutical company focused on developing therapies for diabetes and obesity.